Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.43 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL579513 | 0.84 | OPRM1 (0.60) | HDAC6OPRM1OPRD1OPRK1GRIN2D | |
| SCHEMBL579433 | 0.80 | OPRM1 (0.64) | OPRM1OPRD1OPRK1GRIN2DGRIN3B | |
| SCHEMBL579725 | 0.80 | OPRM1 (0.46) | OPRM1OPRD1OPRK1GRIN2DGRIN3B | |
| SCHEMBL579743 | 0.79 | OPRM1 (0.52) | OPRM1OPRD1OPRK1GRIN2DGRIN3B | |
| SCHEMBL579718 | 0.78 | OPRM1 (0.65) | HDAC6OPRM1OPRD1OPRK1GRIN2D | |
| SCHEMBL580109 | 0.76 | OPRM1 (0.49) | HDAC6OPRM1OPRD1OPRK1GRIN2D | |
| SCHEMBL580094 | 0.73 | PARP10 (0.46) | CHEK2HRH3PARP10 | |
| SCHEMBL3090215 | 0.73 | HDAC6 (0.71) | HDAC6OPRM1OPRD1OPRK1METTL3 | |
| SCHEMBL579934 | 0.73 | HDAC6 (0.53) | HDAC6OPRM1OPRD1OPRK1METTL3 | |
| SCHEMBL13773083 | 0.70 | OPRM1 (0.51) | OPRM1OPRD1OPRK1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735268-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-02-15 | — | — | EP | claimed |
| US-7902372-B2 | Therapy for obesity; using a secondary amino compound | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | claimed |
| US-20080207701-A1 | OPIOID RECEPTOR ANTAGONISTS | CHAPPELL MARK DONALD | 2008-08-28 | — | — | US | claimed |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | claimed |
| US-8338611-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| EP-1735268-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110105571-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| US-7902372-B2 | Therapy for obesity; using a secondary amino compound | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080207701-A1 | OPIOID RECEPTOR ANTAGONISTS | CHAPPELL MARK DONALD | 2008-08-28 | — | — | US | disclosed |
| US-7378448-B2 | Diphenylether amide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207701-A1 | OPIOID RECEPTOR ANTAGONISTS | OPRD1, OPRM1, OPRK1 | HDAC6 1514/4885OPRM1 2/4885OPRD1 1/4885 |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | OPRD1, OPRM1, OPRK1 | HDAC6 1514/4885OPRM1 2/4885OPRD1 1/4885 |
| US-20110105571-A1 | Opioid Receptor Antagonists | OPRD1, OPRM1, OPRK1 | HDAC6 1514/4885OPRM1 2/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.